| Market Capitalization (Millions $) |
1,050 |
| Shares
Outstanding (Millions) |
225 |
| Employees |
370 |
| Revenues (TTM) (Millions $) |
599 |
| Net Income (TTM) (Millions $) |
398 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
CureVac N.V. is a German biotechnology company that focuses on the development of mRNA-based vaccines and therapeutics. The company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, and Florian von der Muelbe.
CureVac's main area of expertise lies in the field of messenger RNA (mRNA) technology, which involves using mRNA molecules to instruct cells to produce specific proteins. This technology has the potential to revolutionize the field of medicine by enabling the development of highly targeted and personalized treatments for various diseases.
CureVac has developed a portfolio of candidate vaccines for diseases such as COVID-19, influenza, rabies, and Zika. The company's most notable achievement has been the development of a COVID-19 vaccine, which has shown promising results in clinical trials.
In addition to vaccines, CureVac is also working on the development of mRNA-based therapies for cancer, rare diseases, and other conditions. The company has collaborated with various pharmaceutical companies and research institutions to advance its pipeline of products.
CureVac went public in 2020 and is listed on the Nasdaq under the ticker symbol CVAC. The company has attracted significant attention and investment due to its innovative mRNA technology and the potential of its products to transform healthcare.
Company Address: Friedrich-Miescher-Strasse 15 Tübingen 72076
Company Phone Number: Stock Exchange / Ticker: NASDAQ CVAC
|
9.22%